Medical Weight Loss for Milford, Delaware Residents

Milford, Delaware residents get physician-supervised weight loss by telehealth from New Hope Weight Loss: a $119 doctor review, then compounded semaglutide from $166/month or tirzepatide from $233/month.

Physician-supervised GLP-1 programs from $166/month, serving Milford through telehealth from our Costa Mesa, California clinic. Doctor review $119. Over 5,400 patients treated.

Open to all of Delaware, including Milford: our Costa Mesa, California physicians treat patients statewide by telehealth, so distance from our office never changes the care you receive. Doctor review just $119 (medication separate).

Why Milford Residents Choose New Hope Weight Loss

At New Hope Weight Loss, every case in Milford is overseen by a named physician, Dr. Anjmun Sharma, MD. You are not handed off to a rotating panel of strangers or a faceless intake bot. Dr. Sharma reviews your history, signs off on your plan, and stays accountable for it. That single point of medical responsibility is rare in telehealth, and it is the reason so many people across Delaware trust us to guide a serious decision about their health.

Milford is part of the area New Hope Weight Loss serves by telehealth. The same compounded semaglutide and tirzepatide protocols, the same flat pricing, and the same bilingual support reach Milford patients at home.

Think of our Costa Mesa clinic as your weight-loss provider even though you live in Milford, because telehealth delivers the same physician-led program to Delaware without asking you to leave home. We care for patients throughout downtown Milford and the greater Kent and Sussex County area of central Delaware. A licensed care coordinator stays reachable by message and phone, so help is a few taps away anywhere in Delaware.

There are no local-office hours to fit your life around, so Milford patients can meet Dr. Sharma on evenings or between work without crossing town. Please note that our compounded semaglutide and tirzepatide are not FDA-approved and are not brand-identical, and results vary from person to person. Though Delaware is small, our reach there is complete: New Hope Weight Loss cares for patients statewide by telehealth from our Costa Mesa, California clinic.

GLP-1 Weight Loss Programs Available

Compounded GLP-1 care, supervised by a physician

The 90-Day Metabolic Reset is built on semaglutide, the same active ingredient you will find in Wegovy and Ozempic. It is priced from $166/mo, with the complete 90-day program at $499, and branded-drug trials averaged about 15 to 17 percent body-weight loss. Compounded semaglutide is not FDA-approved, not brand-identical, and results vary by person. Dr. Sharma manages your care by telehealth, wherever you are in Milford.

Prefer the dual-action route? Tirzepatide

From $233/mo, tirzepatide works on GLP-1 and GIP together. In branded-drug trials, dose-qualified patients reached up to 22.5 percent loss, a peak number that is not typical. Same active ingredient as Mounjaro and Zepbound.

It all starts with a $119 physician review. Medication billed separately. HSA, FSA, Klarna, and Affirm accepted.

How Telehealth Works for Milford

Step 1 of 4: Answer the intake quiz online, sharing your weight history, current health, and what you hope to reach.

Step 2 of 4: Dr. Sharma reviews your responses and connects by secure video, usually within 48 hours, to confirm whether compounded semaglutide or tirzepatide is a reasonable option for you.

Step 3 of 4: A state-licensed 503(a) pharmacy ships your prescription to your Milford address in insulated cold-pack packaging.

Step 4 of 4: Follow-up visits run by video, so you and Dr. Sharma adjust as needed without travel anywhere in .

Frequently Asked Questions, Milford

Does New Hope Weight Loss actually serve Milford, or only Costa Mesa?

We serve both. Our single physical location sits in Costa Mesa, California, and we extend care to Milford, Delaware through telehealth. Residents across neighborhoods like downtown Milford and the greater Kent and Sussex County area of central Delaware qualify the same way. Dr. Anjmun Sharma evaluates whether a compounded GLP-1 plan fits you during your initial video appointment.

Can the whole process be done remotely from Milford?

Yes, it is fully remote. There is no in-person requirement for Milford patients at any stage. You meet Dr. Sharma over video, complete intake online, and receive ongoing support by message. Approved prescriptions arrive at your door in insulated cold-pack shipping that protects the medication during delivery.

How much will a Milford patient pay?

Plan on $119 for the physician visit. Semaglutide runs from $166 monthly, with a $499 option for 90 days, and tirzepatide from $233 monthly. The medication cost is separate from the visit. HSA, FSA, Klarna, and Affirm are all welcome, and Milford residents pay no added distance fee.

What areas of Milford do you serve?

We serve patients from across Milford by telehealth, including downtown Milford and the greater Kent and Sussex County area of central Delaware.

How soon can a Milford patient start treatment?

Most Milford patients complete the online intake in minutes and have Dr. Sharma's video review within about 48 hours. If you are a candidate and telehealth-eligible, medication ships shortly after, so many patients begin within roughly a week of starting.

Milford Residents, Get Started Today

Doctor review $119. Semaglutide from $166/mo. Tirzepatide from $233/mo. Medication separate.

Start My Journey →

New Hope Weight Loss | clinic at 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342 | Serving Milford, Delaware by telehealth. Telehealth availability and eligibility are confirmed during the medical consultation.

Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality.